Talon Therapeutics Inc (fka TLON)

[operating_line]

http://www.businesswire.com/news/home/20151204005117/en/Spectrum-Pharmaceuticals-Highlights-18-Abstracts-57th-Annual

The following are key Marqibo® (vinCRIStine sulfate LIPOSOME injection) related abstracts being presented at the ASH meeting:



Abstract # Type Title First Author Location
1291 Poster Marqibo®, Vincristine Sulfate Liposome Injection, for the Treatment of Advanced, Relapsed or Refractory Philadelphia Chromosome-Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) in an Adolescent Young Adult (AYA) Population Schiller Saturday, Dec 5,
5:30 PM-7:30 PM







Hall A, Level 2

2491 Poster Plasma Vincristine Levels Are 100-Fold Higher with Marqibo®(Vincristine Sulfate LIPOSOME Injection) in Place of Standard Vincristine in Combination Chemotherapy of Patients ≥ 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Wang Sunday, Dec 6,
6:00 PM-8:00 PM







Hall A, Level 2

3965 Poster The Clinical Outcome of Newly Diagnosed Patients >60 Years of Age with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Standard or Liposomal Chemotherapies Ahmed Monday, Dec 7,
6:00 PM-8:00 PM





Hall A, Level 2

3720 Poster Liposomal Vincristine (Marqibo) Combined with Hyper-Cmad As Frontline Therapy for Patients with Acute Lymphoblastic Leukemia: A Result of a Phase II Clinical Trial Sasaki Monday, Dec 7,
6:00 PM-8:00 PM







Hall A, Level 2